All stakeholders, including leaders across industry and health authorities, agree that finding answers to market access is critical to delivering breakthrough medicines to patients. Unfortunately, policies and practices do not always marry up.

This meeting will bring together professionals working with regulatory and value strategies. HTA bodies and regulators are breaking down silos, facilitating access to new promising medicines and increasing efficiencies in assessment processes. Similarly, R&D processes need to adapt to generate the appropriate evidence for registration and reimbursement that should allow patients’ timely access to innovative and promising drugs.

We are bringing together policy makers, developers, and the patients as end users, to keep you ahead of the game with practical solutions.

DIA shares insights in advance of this conference:

• Webinar: Approvals and Access – Overcoming the Final Hurdle of Drug Development
• Podcast: EBE Plots Path from “Flawed Underfunded Biotech System”

Hear a preview of programme committee member Solange Corriol-Rohou’s perspective on evidence generation throughout the life-cycle to support Medicines Adaptive Pathways to Patients (MAPPs) in the IMI project ADAPT SMART Webinar: ADAPT SMART “Putting Stakeholders at the Centre”